Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSH | P09668 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120740 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTHTTHCAR3BRD4 | |
| SCHEMBL539558 | 0.83 | BRD4 (0.50) | ALDH1A1MAPTHTTHCAR3BRD4 | |
| SCHEMBL5971966 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MAPTHTTHCAR3BRD4 | |
| SCHEMBL5971968 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MAPTHTTHCAR3BRD4 | |
| SCHEMBL5120767 | 0.80 | MAPT (0.39) | ALDH1A1MAPTHTTHCAR3BRD4 | |
| SCHEMBL5120760 | 0.80 | MAPT (0.39) | ALDH1A1MAPTHTTHCAR3BRD4 | |
| SCHEMBL2018202 | 0.76 | CYP1A2 (0.53) | ALDH1A1MAPTHTTCTSBCTSH | |
| SCHEMBL5972031 | 0.76 | NPC1 (0.43) | ALDH1A1MAPTBRD4POLB | |
| SCHEMBL5126018 | 0.75 | MAPT (0.51) | ALDH1A1MAPTHCAR3POLB | |
| SCHEMBL5126008 | 0.75 | MAPT (0.51) | ALDH1A1MAPTHCAR3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | claimed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058383-A1 | Androgen Receptor Modulators | NR5A1, ESRRA, AR | ALDH1A1 567/4885MAPT 3258/4885HTT 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.